ATE413384T1 - Matrixmetalloproteinaseinhibitoren - Google Patents

Matrixmetalloproteinaseinhibitoren

Info

Publication number
ATE413384T1
ATE413384T1 AT04765231T AT04765231T ATE413384T1 AT E413384 T1 ATE413384 T1 AT E413384T1 AT 04765231 T AT04765231 T AT 04765231T AT 04765231 T AT04765231 T AT 04765231T AT E413384 T1 ATE413384 T1 AT E413384T1
Authority
AT
Austria
Prior art keywords
alkyl
alkylaryl
cor
optionally substituted
bond
Prior art date
Application number
AT04765231T
Other languages
English (en)
Inventor
Simon Gaines
Ian Holmes
Stephen Martin
Stephen Watson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE413384T1 publication Critical patent/ATE413384T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Soft Magnetic Materials (AREA)
  • Indole Compounds (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Lubricants (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04765231T 2003-09-13 2004-09-10 Matrixmetalloproteinaseinhibitoren ATE413384T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0321538.1A GB0321538D0 (en) 2003-09-13 2003-09-13 Therapeutically useful compounds

Publications (1)

Publication Number Publication Date
ATE413384T1 true ATE413384T1 (de) 2008-11-15

Family

ID=29227079

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08163972T ATE502922T1 (de) 2003-09-13 2004-09-10 Matrix-metalloproteinaseinhibitoren
AT04765231T ATE413384T1 (de) 2003-09-13 2004-09-10 Matrixmetalloproteinaseinhibitoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08163972T ATE502922T1 (de) 2003-09-13 2004-09-10 Matrix-metalloproteinaseinhibitoren

Country Status (28)

Country Link
US (3) US7601729B2 (de)
EP (3) EP1663970B1 (de)
JP (3) JP2007505081A (de)
KR (3) KR20060120648A (de)
CN (1) CN1849306B (de)
AT (2) ATE502922T1 (de)
AU (1) AU2004272280C1 (de)
BR (1) BRPI0413791A (de)
CA (1) CA2538315C (de)
CY (1) CY1109400T1 (de)
DE (2) DE602004017622D1 (de)
DK (1) DK1663970T3 (de)
ES (2) ES2314436T3 (de)
GB (1) GB0321538D0 (de)
HR (1) HRP20080668T3 (de)
IL (1) IL173305A (de)
IS (2) IS2622B (de)
MA (1) MA28039A1 (de)
MX (1) MXPA06002458A (de)
NO (1) NO20060540L (de)
NZ (2) NZ545211A (de)
PL (1) PL1663970T3 (de)
PT (1) PT1663970E (de)
RU (2) RU2370488C2 (de)
SG (1) SG145685A1 (de)
SI (1) SI1663970T1 (de)
WO (1) WO2005026120A1 (de)
ZA (1) ZA200602070B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
NZ560803A (en) * 2005-02-22 2010-10-29 Ranbaxy Lab Ltd 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
NZ574905A (en) * 2006-08-22 2011-12-22 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
AU2013200728B2 (en) * 2006-08-22 2014-12-18 Sun Pharmaceutical Industries Limited Matrix metalloproteinase inhibitors
EP2520561B1 (de) 2007-06-08 2016-02-10 MannKind Corporation IRE-1a-Inhibitoren
FR2949463B1 (fr) * 2009-08-26 2011-09-16 Commissariat Energie Atomique Inhibiteurs de mmp
WO2012014114A1 (en) 2010-07-30 2012-02-02 Ranbaxy Laboratories Limited Matrix metalloproteinase inhibitors
SG188642A1 (en) 2010-09-24 2013-05-31 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors
US20160045463A1 (en) 2012-11-28 2016-02-18 Universidad De Salamanca Use of metalloprotease inhibitors in the treatment of polycystic liver diseases
SMT202200201T1 (it) 2016-02-12 2022-07-21 Cytokinetics Inc Derivati di tetraidroisochinolina
JP7143334B2 (ja) * 2017-06-13 2022-09-28 エシコン エルエルシー 治癒を制御させる手術用ステープラ

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) * 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1995029901A1 (en) * 1994-04-28 1995-11-09 Uniroyal Chemical Company, Inc. Fungicidal azole derivatives
SK73998A3 (en) * 1995-12-06 1999-02-11 Astra Pharma Prod Compounds
CA2251820C (en) * 1996-04-19 2007-03-27 Akzo Nobel Nv Substituted benzylamines and their use for the treatment of depression
HRP970246B1 (en) * 1996-05-15 2002-04-30 Bayer Ag Substituted oxobutric acids as matrix metalloprotease inhibitors
US6870058B2 (en) * 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US20050065353A1 (en) * 1996-12-03 2005-03-24 Smith Amos B. Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
US5789605A (en) * 1996-12-03 1998-08-04 Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof
US6096904A (en) 1996-12-03 2000-08-01 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US6242616B1 (en) * 1996-12-03 2001-06-05 The Trustees Of The University Of Pennsylvania Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives
US5804581A (en) * 1997-05-15 1998-09-08 Bayer Corporation Inhibition of matrix metalloproteases by substituted phenalkyl compounds
US6608052B2 (en) * 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
CA2490819A1 (en) * 2001-04-13 2002-10-24 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7102008B2 (en) * 2002-08-01 2006-09-05 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme
PL378238A1 (pl) * 2002-11-19 2006-03-20 Galderma Research & Development, S.N.C. Związki biaromatyczne, które aktywują receptory typu PPAR<$Egamma>, oraz ich zastosowanie w kompozycjach kosmetycznych albo farmaceutycznych
GB0312654D0 (en) * 2003-06-03 2003-07-09 Glaxo Group Ltd Therapeutically useful compounds
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
GB0321538D0 (en) * 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
NZ560803A (en) * 2005-02-22 2010-10-29 Ranbaxy Lab Ltd 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases
NZ574905A (en) * 2006-08-22 2011-12-22 Ranbaxy Lab Ltd Matrix metalloproteinase inhibitors

Also Published As

Publication number Publication date
ES2362954T3 (es) 2011-07-15
IS8268A (is) 2006-01-26
RU2006106850A (ru) 2007-10-20
JP2012107031A (ja) 2012-06-07
EP1663970B1 (de) 2008-11-05
RU2370488C2 (ru) 2009-10-20
KR20060120648A (ko) 2006-11-27
SG145685A1 (en) 2008-09-29
BRPI0413791A (pt) 2006-11-07
CN1849306B (zh) 2014-01-29
KR20120007566A (ko) 2012-01-20
IS2622B (is) 2010-05-15
RU2008146479A (ru) 2010-06-20
JP2007505081A (ja) 2007-03-08
CN1849306A (zh) 2006-10-18
EP1663970A1 (de) 2006-06-07
US20090082377A1 (en) 2009-03-26
SI1663970T1 (sl) 2009-04-30
US20100029699A1 (en) 2010-02-04
MXPA06002458A (es) 2006-06-20
EP2042488B1 (de) 2011-03-23
DK1663970T3 (da) 2009-01-12
DE602004017622D1 (de) 2008-12-18
IL173305A0 (en) 2006-06-11
US8343986B2 (en) 2013-01-01
HRP20080668T3 (hr) 2009-02-28
EP2042488A1 (de) 2009-04-01
AU2004272280B2 (en) 2011-04-21
IS8843A (is) 2009-08-19
JP2011231118A (ja) 2011-11-17
DE602004031991D1 (de) 2011-05-05
CA2538315C (en) 2014-04-08
NO20060540L (no) 2006-04-04
AU2004272280A1 (en) 2005-03-24
GB0321538D0 (en) 2003-10-15
KR20130079628A (ko) 2013-07-10
US7601729B2 (en) 2009-10-13
HK1092141A1 (en) 2007-02-02
CA2538315A1 (en) 2005-03-24
PT1663970E (pt) 2009-01-09
CY1109400T1 (el) 2014-07-02
US8263602B2 (en) 2012-09-11
US20060293353A1 (en) 2006-12-28
ES2314436T3 (es) 2009-03-16
IL173305A (en) 2011-01-31
PL1663970T3 (pl) 2009-04-30
MA28039A1 (fr) 2006-07-03
ATE502922T1 (de) 2011-04-15
WO2005026120A1 (en) 2005-03-24
ZA200602070B (en) 2007-05-30
EP2295408A1 (de) 2011-03-16
AU2004272280C1 (en) 2011-10-27
NZ545211A (en) 2009-01-31
NZ573479A (en) 2010-09-30

Similar Documents

Publication Publication Date Title
IS8843A (is) Hálfmálmaprótínasa hindra mót
ATE362910T1 (de) Matrix metalloprotease inhibitoren
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
DE3883140D1 (de) Imidazo(2,1-b)benzothiazole und ihre saeureadditionssalze, verfahren und zwischenprodukte zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zubereitungen.
EA200100090A2 (ru) Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции
AR029468A1 (es) Derivados de aminoacidos n-mercaptoacilados, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
DK1010698T3 (da) Hidtil ukendte derivater af 1,2-dithiolan, fremgangsmåde til fremstiling deraf og farmaceutiske sammensætninger indeholdende dem
YU74201A (sh) Nova sinteza prstena piperazina
ATE239021T1 (de) Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
EA200301079A1 (ru) Терапевтическое средство по поводу повышенной чувствительности мочевого пузыря
WO2002074764A3 (en) Piperazine derivatives and their use as 5-ht1b ligands
EA200001077A3 (ru) Новые соединения аминопирролина, способ их получения и содержащие их фармацевтические композиции
DK1188752T3 (da) Fremgangsmåde til fremstilling af substitueret alkylaminderivat
ES2058182T3 (es) Analogos de mitomicina. un procedimiento para su preparacion y composiciones farmaceuticas.
DK0955310T3 (da) Hidtil ukendte (3,4,7,8,9,10)-hexahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-carboxylsyrederivater, fremgangsmåde til fremstilling af disse og anvendelse af disse til fremstilling af lægemidler
NO903084D0 (no) Farmasoeytisk anvendbare thiazol-derivater og fremgangsmaate for deres fremstilling.
GB1183442A (de)
IT1213440B (it) 2-ditioalchil-diidropiridine, un metodo per la loro preparazione e composizioni farmaceutiche chele contengono.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1663970

Country of ref document: EP